摘要
目的 研究基质金属蛋白酶 -2(MMP2)、基质金属蛋白酶组织抑制剂- 2(TIMP2)在肾透明细胞癌(RCCC)中的表达及意义。 方法 采用免疫组织化学SAB法测定 44例RCCC及20例正常肾组织中MMP2与TIMP2蛋白的表达。44例RCCC中病理分级G1 14例,G2 28例,G3 2例,病理分期pT1 24例,pT2 8例,pT3 12例。 结果 MMP2在RCCC中的阳性表达率为 79. 6% (35 /44),高于正常肾组织的 15% ( 3 /20 ),MMP2表达与RCCC病理分级、分期呈正相关 (r=0. 6316,P<0. 01;r=0.5096,P<0. 01);TIMP2在RCCC中的阳性表达率为 100% (44 /44),高于正常肾组织的 35% (7 /20),但TIMP2表达与RCCC病理分期、分级无相关性(r=0.2404,P>0. 05;r=-0.1236,P>0. 05)。在RCCC中MMP2与TIMP2阳性表达率无相关性 (r=0.2015,P>0. 05 )。 结论 RCCC中MMP2表达与RCCC病理分期、分级呈正相关,提示MMP2免疫活动增高不良预后有关系,而TIMP2的反常表达以及作用值得进一步深入研究。MMP2可以作为判断RCCC预后的分子指标。
Objective To investigate the expression of matrix metalloproteinases2 (MMP2)and tissue inhibitors of metalloproteinases2 (TIMP2) in renal clear cell carcinoma (RCCC),and to explore their correlation with pathologic grade and stage of the tumors. Methods The expression of MMP2 and TIMP2 in 44 cases of RCCC and 20 cases of normal renal tissue were determined with immunohistochemical SAB assay.Of the 44 cases of RCCC,14 were at G 1,28 at G 2 and 2 at G 3 according to pathologic grading;and 24 cases were at pT 1,8 at pT 2 and 12 at pT 3 according to pathologic staging. Results The expression of MMP2 in RCCC was 79.6%(35/44),which was higher than that in normal renal tissue (15%, 3/20).The high expression of MMP2 was positively correlated with the grade and stage of RCCC (r=0.6316,P<0.01;r =0.5096,P<0.01,respectively).The expression of TIMP2 in RCCC was 100%(44/44),which was higher than that in normal renal tissue (35%,7/20);but its expression was not correlated with the stage and grade of RCCC (r=0.2404,P>0.05;r=-0.1236,P>0.05,respectively).The expression of MMP2 was not correlated with that of TIMP2 in RCCC (r=0.2015,P>0.05). Conclusions MMP2 expression is positively correlated with the grade and stage of renal cancer, indicating that increased expression of MMP2 protein in RCCC is associated with poor prognosis of RCCC.By contrast,the abnormal expression of TIMP2 and its function of inhibiting tumor infiltration and migration need further investigation.MMP2 can be used as a useful molecular marker for prognosis of RCCC.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2005年第3期184-187,共4页
Chinese Journal of Urology
